Anthony E. Bolton
Keine laufenden Positionen mehr
Karriereverlauf von Anthony E. Bolton
Ehemalige bekannte Positionen von Anthony E. Bolton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1992 | 01.01.2008 |
Gründer | 01.01.1992 | 01.01.2008 | |
Sheffield Hallam University | Corporate Officer/Principal | 01.01.1985 | 01.01.1995 |
InterMune Life Sciences, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1992 | 01.01.1995 |
Gründer | 01.01.1992 | 01.01.1995 | |
Jessop Hospital For Women | Corporate Officer/Principal | 01.01.1992 | 01.01.1995 |
St. Bartholomew's Hospital | Corporate Officer/Principal | 01.01.1976 | 01.01.1979 |
CARDIOL THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.01.2017 | - |
Gründer | 19.01.2017 | - |
Ausbildung von Anthony E. Bolton
University of London | Undergraduate Degree |
The University of Reading | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 6 |
Kanada | 4 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Founder | 3 |
Corporate Officer/Principal | 3 |
Sektoral
Consumer Services | 4 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
St. Bartholomew's Hospital | |
InterMune Life Sciences, Inc. | |
Jessop Hospital For Women |
- Börse
- Insiders
- Anthony E. Bolton
- Erfahrung